Hyaluronidase with pH‐responsive Dextran Modification as an Adjuvant Nanomedicine for Enhanced Photodynamic‐Immunotherapy of Cancer
Authors:
- 22 May 2019
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 29 (29)
Abstract
The condensed tumor extracellular matrix (ECM) consisting of cross‐linked hyaluronic acid (HA) is one of key factors that results in the aberrant tumor microenvironment (TME) and the resistance to various types of therapies. Herein, hyaluronidase (HAase) is modified by a biocompatible polymer, dextran (DEX), via a pH‐responsive traceless linker. The formulated DEX‐HAase nanoparticles show enhanced enzyme stability, reduced immunogenicity, and prolonged blood half‐life after intravenous injection. With efficient tumor passive accumulation, DEX‐HAase within the acidic TME would be dissociated to release native HAase, which afterward triggers the breakdown of HA to loosen the ECM structure, subsequently leading to enhanced penetration of oxygen and other therapeutic agents. The largely relieved tumor hypoxia would promote the therapeutic effect of nanoparticle‐based photodynamic therapy (PDT), accompanied by the reverse of the immunosuppressive TME to boost cancer immunotherapy. Interestingly, the therapeutic responses achieved by the combination of PDT and anti‐programmed death‐ligand 1 (anti‐PD‐L1) checkpoint blockade therapy could be significantly enhanced by pretreatment with DEX‐HAase. In addition to destructing tumors with direct light exposure, a robust abscopal effect is achieved after such treatment, which is promising for tumor metastasis inhibition. The work presents a new type of adjuvant nanomedicine to assist photodynamic‐immunotherapy of cancer, by effective modulation of TME.Keywords
Funding Information
- National Natural Science Foundation of China (51525203)
- Collaborative Innovation Center of Suzhou Nano Science and Technology
This publication has 61 references indexed in Scilit:
- Tumor Microenvironment Complexity: Emerging Roles in Cancer TherapyCancer Research, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Enhanced Systemic Immune Reactivity to a Basal Cell Carcinoma Associated Antigen Following Photodynamic TherapyClinical Cancer Research, 2009
- Cancer and the tumor microenvironment: a review of an essential relationshipCancer Chemotherapy and Pharmacology, 2008
- Diffusion in Brain Extracellular SpacePhysiological Reviews, 2008
- Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathwaysMatrix Biology, 2007
- Review. Hyaluronan: A Powerful Tissue Engineering ToolTissue Engineering, 2006
- Synergism of Epidermal Growth Factor Receptor–Targeted Immunotherapy With Photodynamic Treatment of Ovarian Cancer In VivoJNCI: Journal of the National Cancer Institute, 2005
- Hyaluronan catabolism: a new metabolic pathwayEuropean Journal of Cell Biology, 2004
- Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell lineInternational Journal of Cancer, 2001